NAMS
NewAmsterdam Pharma Company N.V. (NASDAQ)
Healthcare — Biotechnology
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Price History
Fundamentals
| Market Cap | $4.11B |
| P/E Ratio (TTM) | - |
| Forward P/E | -27.65 |
| EPS (TTM) | $-1.78 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | 2.10% |
| ROE | -29.49% |
| Debt/Equity | 0.00 |
| Recommendation | Strong Buy 1.4 |
| Analyst Target | $49.73 |
| Analysts | 14 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 81.8 |
| Beta | 0.08 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $42.21 |
| 52-Week Low | $18.70 |
| 50-Day Avg | $32.68 |
| 200-Day Avg | $33.56 |
| Avg Volume | $1.29M |
| Volume | 856.0K |
Performance Analysis
BULLISHNAMS shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jul 02, 2026 13:21 UTC
Back to Screener Export Report